ZA975013B - Modified factor VII. - Google Patents

Modified factor VII.

Info

Publication number
ZA975013B
ZA975013B ZA9705013A ZA975013A ZA975013B ZA 975013 B ZA975013 B ZA 975013B ZA 9705013 A ZA9705013 A ZA 9705013A ZA 975013 A ZA975013 A ZA 975013A ZA 975013 B ZA975013 B ZA 975013B
Authority
ZA
South Africa
Prior art keywords
factor vii
modified factor
modified
vii
factor
Prior art date
Application number
ZA9705013A
Other languages
English (en)
Inventor
Lars Christian Petersen
Charles E Hart
Ulla Hedner
Mirella Ezban Rasmussen
Original Assignee
Zymogenetics Inc
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Novo Nordisk As filed Critical Zymogenetics Inc
Publication of ZA975013B publication Critical patent/ZA975013B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA9705013A 1996-06-07 1997-06-06 Modified factor VII. ZA975013B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/660,289 US5833982A (en) 1991-02-28 1996-06-07 Modified factor VII

Publications (1)

Publication Number Publication Date
ZA975013B true ZA975013B (en) 1997-12-08

Family

ID=24648892

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9705013A ZA975013B (en) 1996-06-07 1997-06-06 Modified factor VII.

Country Status (17)

Country Link
US (2) US5833982A (enExample)
EP (1) EP0910580A1 (enExample)
JP (1) JP2000513720A (enExample)
KR (1) KR20000016415A (enExample)
CN (2) CN1515318A (enExample)
AU (1) AU735012B2 (enExample)
BR (1) BR9709661A (enExample)
CA (1) CA2256761A1 (enExample)
CZ (1) CZ394698A3 (enExample)
HU (1) HUP0003077A3 (enExample)
IL (1) IL127099A0 (enExample)
NO (1) NO985668L (enExample)
PL (1) PL330365A1 (enExample)
RU (1) RU2211704C2 (enExample)
UA (1) UA68333C2 (enExample)
WO (1) WO1997047651A1 (enExample)
ZA (1) ZA975013B (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US20040087498A1 (en) * 1991-02-28 2004-05-06 Novo Nordisk Health Care Ag Modified factor VII
WO1999003498A1 (en) * 1997-07-18 1999-01-28 Novo Nordisk A/S USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6406488B1 (en) 1998-08-27 2002-06-18 Heartstent Corporation Healing transmyocardial implant
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
EP1059302A1 (en) 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
NZ521257A (en) * 2000-02-11 2004-10-29 Maxygen Aps Factor VII or VIIa-like molecules
WO2001079444A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc Albumin fusion proteins
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
AU2001269803A1 (en) * 2000-06-20 2002-01-02 The Trustees Of The University Of Pennsylvania Compositions and methods for modulating muscle cell and tissue contractility
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
NZ526269A (en) 2000-12-06 2004-11-26 Aventis Pharma Gmbh Guanidine and amidine derivatives as factor Xa inhibitors having antithrombotic effect
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
AU2002249096B2 (en) * 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
HUP0304050A3 (en) * 2001-05-02 2005-12-28 Novo Nordisk As Modified fvii in treatment of ards
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
AU2002326135A1 (en) * 2001-09-10 2003-03-24 Florence Medical Ltd. Individual ffr determination for lesions of a multi-lesioned blood vessel
EP2305311A3 (en) 2001-10-10 2011-07-20 BioGeneriX AG Glycoconjugation of peptides
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
AU2002336920A1 (en) * 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
EP1314733A1 (en) 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
BR0215216A (pt) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
CN1606452A (zh) * 2001-12-21 2005-04-13 诺沃娜第克公司 修饰的因子ⅶ多肽的液体组合物
WO2003093465A1 (en) * 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
ES2377959T3 (es) * 2002-05-03 2012-04-03 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de factor VII modificado
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
KR20050013148A (ko) * 2002-06-21 2005-02-02 노보 노르디스크 에이/에스 인자 ⅶ 폴리펩티드의 안정화된 고체 조성물
EP1549677B1 (en) * 2002-09-30 2011-04-13 Bayer HealthCare LLC FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY
US7358268B2 (en) 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US20040176704A1 (en) * 2003-03-04 2004-09-09 Stevens Timothy A Collection device adapted to accept cartridge for point of care system
CA2518327A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
DK1608745T3 (da) * 2003-03-20 2009-06-15 Bayer Healthcare Llc FVII eller FVIIa-Varianter
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
US20040202726A1 (en) * 2003-04-10 2004-10-14 Deshay Samuel L. Topical blood pressure composition
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US7317027B2 (en) 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
US7223780B2 (en) 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479680A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole derivatives as Factor Xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
CN1780638B (zh) * 2003-05-23 2010-04-14 诺和诺德医疗保健公司 氧化硅涂层玻璃作为容器内壁材料的用途及以该材料作内壁的容器
US7029675B1 (en) * 2003-06-04 2006-04-18 Shu-Wha Lin Hepsin antagonist and methods of use
DK1644504T3 (da) * 2003-06-19 2010-05-25 Bayer Healthcare Llc Faktor VII- eller -VIIA-Gla-domænevarianter
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
ATE507822T1 (de) * 2003-12-19 2011-05-15 Novo Nordisk Healthcare Ag Stabilisierte zusammensetzungen von faktor-vii- polypeptiden
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
JP2008514677A (ja) * 2004-09-29 2008-05-08 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 陰イオン交換物質からの分画溶出によるｖｉｉ因子ポリペプチドのバルクの精製
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
KR20100016160A (ko) 2007-04-03 2010-02-12 바이오제너릭스 에이지 글리코페길화 ｇ―ｃｓｆ를 이용하는 치료 방법
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
CN101965200B (zh) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 缀合的因子ⅷ分子
NZ593815A (en) 2008-12-19 2013-05-31 Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
NZ623576A (en) 2010-03-19 2015-11-27 Baxter Healthcare Sa Tfpi inhibitors and methods of use
KR101294351B1 (ko) * 2010-05-27 2013-08-07 동국대학교 산학협력단 뇌혈전 형광영상기술을 이용한 뇌졸중 동물모델의 뇌경색 영역의 크기 예측 방법
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
ES2935489T3 (es) 2012-02-15 2023-03-07 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
WO2013141965A1 (en) 2012-03-21 2013-09-26 Baxter International Inc. Tfpi inhibitors and methods of use
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
EP3324960A4 (en) * 2015-07-22 2019-01-23 Iconic Therapeutics, Inc. METHOD FOR TREATING DISORDER IN CONNECTION WITH ANGIOGENESIS AND NEOVASCULARIZATION
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
EP3402537B1 (en) 2016-01-15 2021-01-06 Rigshospitalet Quantitative pet imaging of tissue factor expression using 18f-labelled active site inhibited factor vii
US20190358351A1 (en) 2016-11-17 2019-11-28 Minerva Imaging Aps 177-lu labeled active site inhibited factor vii
IL319473A (en) 2016-12-02 2025-05-01 Bioverativ Therapeutics Inc Methods for treating hemophilic arthritis using chimeric blood clotting factors
DK3793588T3 (da) 2018-05-18 2025-06-16 Bioverativ Therapeutics Inc Fremgangsmåder til behandling af hæmofili a

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
AU5864086A (en) * 1985-04-22 1986-11-18 Genetics Institute Inc. High yield production of active factor ix
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US4829052A (en) * 1986-06-11 1989-05-09 Monsanto Company Serine protease inhibitors
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
EP0278727A3 (en) 1987-02-10 1990-03-14 Glaxo Group Limited 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-(substituted amino)ethanol derivatives and their use in the treatment of respiratory disease
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) * 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5023236A (en) * 1988-04-07 1991-06-11 Corvas, Inc. Factor VII/VIIA active site inhibitors
US5258180A (en) * 1988-09-02 1993-11-02 Genetech, Inc. Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
AU4338689A (en) * 1988-09-23 1990-04-18 Corvas, Inc. Peptidyl inhibitors of the initiation of coagulation
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
US5190919A (en) * 1989-11-13 1993-03-02 Board Of Regents, The University Of Texas System Antihemostatic factor vii peptides
EP0521873B1 (en) 1990-01-29 1999-06-02 Zymogenetics, Inc. Anticoagulant proteins
US5278144A (en) * 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5817788A (en) 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5861374A (en) 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
ATE273393T1 (de) * 1991-02-28 2004-08-15 Zymogenetics Inc Modifizierter faktor-vii
WO1994027631A1 (en) * 1993-05-21 1994-12-08 Zymogenetics, Inc. Modified factor vii
RU2022561C1 (ru) * 1991-03-05 1994-11-15 Харьковский государственный университет им.А.М.Горького Противоишемическое средство
US5326559A (en) * 1991-05-16 1994-07-05 Miller D Douglas Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
US5419760A (en) * 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
GB9301093D0 (en) * 1993-01-20 1993-03-10 Rca Thomson Licensing Corp Digital video tape recorder for digital hdtv
US5648331A (en) * 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury

Also Published As

Publication number Publication date
NO985668D0 (no) 1998-12-04
CN1221427A (zh) 1999-06-30
IL127099A0 (en) 1999-09-22
BR9709661A (pt) 2000-04-25
RU2211704C2 (ru) 2003-09-10
KR20000016415A (ko) 2000-03-25
AU735012B2 (en) 2001-06-28
US5833982A (en) 1998-11-10
HUP0003077A2 (hu) 2000-12-28
US6168789B1 (en) 2001-01-02
CA2256761A1 (en) 1997-12-18
HUP0003077A3 (en) 2003-01-28
JP2000513720A (ja) 2000-10-17
CN1515318A (zh) 2004-07-28
CZ394698A3 (cs) 1999-04-14
WO1997047651A1 (en) 1997-12-18
NO985668L (no) 1999-02-04
EP0910580A1 (en) 1999-04-28
CN1131872C (zh) 2003-12-24
PL330365A1 (en) 1999-05-10
AU3090697A (en) 1998-01-07
UA68333C2 (en) 2004-08-16

Similar Documents

Publication Publication Date Title
ZA975013B (en) Modified factor VII.
ZA9710429B (en) Broad-spectrumδ-endotoxins.
ZA979199B (en) Aminothiophenecarboxamides.
ZA976168B (en) 3-Ureido-pyridofurans and -pyridothiophenes.
ZA977206B (en) Arylalkanoylpyridazines.
ZA978304B (en) 3-alkyl-3-phenyl-piperidines.
EP0664969A3 (de) Skischuh.
ZA9711567B (en) Compounds.
ZA975861B (en) Bromotiacumicin compounds.
ZA97572B (en) 1-pyrazol-3-ylethyl-4-indol-3-ylpiperidines.
ZA97928B (en) Novel heteroaryl-oxazolidinones.
ZA974052B (en) New benzothiazolinones.
ZA983705B (en) Pregnan-3-ol-20-ones.
ZA976022B (en) Cycloalkano-pyridines.
ZA971466B (en) Endothelin-receptor-antagonists.
ZA979404B (en) Aspirinate compounds.
EP0672364A3 (de) Skischuh.
ZA974056B (en) New thiazolopyridines.
GR3034943T3 (en) Medrogestrone.
EP0671133A3 (de) Skischuh.
ZA981309B (en) 4-aminoalkoxy-1H-benzoimidazoles.
ZA971474B (en) Endothelin-receptor-antagonists.
ZA975469B (en) X14-mannitol.
ZA977142B (en) Belt-lock.
ZA983698B (en) Estrenes.